Financial News Feed

Stronger Sell Today ADMA ranks #5117 as SELL CANDIDATE #5117 Weaker Sell

ADMA Biologics Inc stock forecast

ADMA stock forecast

Daily Insider Ratings Round Up 5/23/19
08:04pm, Sunday, 26'th May 2019
No summary available....

Read more

ADMA Bio closes $52M capital raise
08:27pm, Tuesday, 21'st May 2019
No summary available....

Read more

ADMA Bio down 5% on pricing equity offering
11:33am, Friday, 17'th May 2019
No summary available....

Read more

ADMA Bio down 10% after hours on equity offering
08:52pm, Wednesday, 15'th May 2019
No summary available....

Read more

No summary available....

Read more

ADMA Biologics beats by $0.04, beats on revenue
09:05pm, Wednesday, 08'th May 2019
No summary available....

Read more

No summary available....

Read more

No summary available....

Read more

RAMSEY, N.J. and BOCA RATON, Fla., April 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA" or the "Company"), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection. The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti- pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti- pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti- pneumococcal immune globulin. This patent will enable ADMA to protect its proprietary rights and at the same time attract collaborators interested in the development, marketing and commercialization of a much needed therapeutic for the treatment and prevention of infection in immune compromised, immunodeficient, and elderly patients who are poorly responsive to available S. pneumonia vaccines....

Read more

No summary available....

Read more

ADMA Biologics Inc (NASDAQ: ADMA) is making a run for the top in the market this morning, and for good reason. The company announced that it has received an FDA approval, meaning that it can now ma…...

Read more

Pura Vida Investments Llc decreased its stake in Adma Biologics Inc (ADMA) by 93.49% based on its latest 2018Q4 regulatory filing with the SEC. Pura Vida Investments Llc sold 534,147 shares as the com...

Read more

ADMA Biologics Inc. (NASDAQ:ADMA) and Autolus Therapeutics plc (NASDAQ:AUTL) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitabili...

Read more

WhoTrades - Social network for traders...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank